1Griffith TS,Kemp TJ.The topoisomerase I inhibitor topotecan increases the sensitivity of prostate tumor cells to TRAIL/Apo-2L-induced apoptosis.Cancer Chemother Pharmacol,2003;52(3):175～84
2Steinbach D,Sell W,Voigt A et al.BCRP gent expression is asso ciated with a poor response to remission induction therapy in childhood acute myeloid leukemia.Leukemia,2002;16(8):1443～7
3Lee ST,Jang JH,Suh HC.Idarubicin,cytarabine,and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome.Am J Hematol,2001;68(4):237～45
5Cohen JD,Schmitt CL Robins HI.Radiosensitization of human T-cell leukmia by thymidine and 41.8 degree C hyperthermia in vitro.Radiat Res,1991;126(3):372～3
6Thompson CB.Apoptosis in the Pathogenesis and Treatment of Disease.Science,1995;267(5203):1456
3Fiorica J, Holloway R, Ndubisi B, et al. Phase Ⅱ trial of topotecan and cisplatin in persistent or recurrent squamous and momsquamous carcinomas of the cervix [ J ]. Cynecol Oncol, 2002,85 ( 1 ) : 89
4Cabanillas F. The role of topoisomerase- Ⅰ inhibitors in the treatmentof non-Hodgkin's lymphoma[ J]. Semin Hematol, 1999,36(4 Suppl 8) :11
5Fletcher TM, Sun D,Salazar M, et al. Effect of DNA secondary structure on human telomerase activity [ J ]. Biochemistry, 1998, 37 (16) :5536
